Project Grant K23HL171862
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$180K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This $163,080 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to study the regulatory T cell (Treg) response in children with severe viral pneumonia. The grant supports research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in children, assess how the lung microenvironment affects Treg pro-recovery functions, and identify Treg transcriptional...
This federal Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research focused on understanding how disruptions to early-life gut microbiome colonization can impair the development and function of key lung immune and epithelial cells. The research aims to elucidate how these microbiome-driven changes contribute to increased susceptibility to respiratory infections and the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $160,518 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Children's Research Institute (CRI) in Washington, DC. The grant, awarded on August 15, 2024, supports a Phase I clinical trial (NCT 05141058) to evaluate the safety and preliminary efficacy of using donor-derived SARS-CoV-2-specific T cells for prophylaxis against SARS-CoV-2 infection in patients after hematopoietic stem cell transplant. The...
This $844,386 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports genomic research to advance the understanding and treatment of childhood interstitial lung diseases (CHILD). The key objectives are to: Expand profiling of 300 CHILD lung biopsy samples to define patient subgroups based on molecular profiles, develop a CHILD classifier, and assess the clinical significance of the subgroups. Analyze...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $676,499 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant's objective is to investigate the mechanisms behind successful and failed allogeneic virus-specific T-cell therapy for infections in hematopoietic stem cell transplant recipients. The project aims to improve understanding of both patient and viral factors that influence...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $561,030 to the Children's Research Institute to conduct research aimed at enhancing the efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation. The project, funded under CFDA 93.837 (Cardiovascular Diseases Research), will focus on developing CD52 knockout virus-specific T cells to improve persistence and function in the presence of immunosuppressive therapies like...
The Research Institute at Nationwide Children's Hospital (RINCH) received a $711,039 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The project, titled "Role of Cardiac m6A Methyltransferases", aims to investigate the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and determine if their dysregulation contributes to the pathogenesis of fetal dilated...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, with a performance period from September 1, 2024 to August 31, 2029, will support the development of a 3D AI-powered map of genetic factors underlying normal and aberrant childhood lung development, including in the context of childhood interstitial lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $145,910 to The Children's Hospital of Philadelphia (CHOP) to conduct a prospective observational study on post-cardiac arrest myocardial dysfunction and inflammation in critically ill children. The study will leverage advanced echocardiographic imaging and biomarker assessment to examine associations between these measures and clinical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $445,000.00 in funding to The Children's Hospital of Philadelphia (CHOP) from March 17, 2025 to February 29, 2028. The purpose of this grant is to conduct research to better understand the role of neutrophil extracellular traps (NETs) in host defense and inflammatory diseases, as well as to explore the potential of NET-directed...